Insulet (NASDAQ:PODD) Stock

INSULET CORP

Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.

Insulet Corp

Wall Street traded slightly lower by midday Friday, as investors adopted a wait-and-see stance ahead of a potential trade breakthrough, with high-stakes negotiations between U.S. officials—led by Treasury Secretary Scott Bessent—and Chinese authorities set to <a href="https://www.benzinga.com/topic/tariffs">unfold over the weekend.</a>
President Donald Trump signaled that tariffs on Chinese goods could be slashed from the current 145% to 80%, though that figure remains significantly higher than pre-Liberation Day levels, prompting continued caution among market participants.
Equities gave back a portion of Thursday's gains as sentiment turned more defensive, while gold rebounded 1% to $3,330 per ounce, partially offsetting losses from the previous session.
Oil prices extended their rally, climbing further above $60 a barrel amid an improved global demand outlook, putting crude on track for its strongest weekly performance since late 2024. Natural gas followed suit, with Henry Hub futures rising 4.4%.
In fixed income, Treasury yields held steady, with the 10-year yield hovering around 4.37%.
Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) took a breather after Thursday's 6.4% surge, trading just above $102,500.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,650.98</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,003.04</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,017.97</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,179.33</td>
<td>-0.5%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 1:10 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.2% lower to $563.80.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.4% to $412.10.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;eased 0.2% to $487.38.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.3% lower to $200.54.</li>
<li>The&nbsp;Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 0.9%; the&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, down 0.5%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul class="wp-block-list">
<li>McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) up 0.48%</li>
<li>Monster Beverage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) up 2.02%</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) down 2.28%</li>
<li>TKO Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>) down 4.10%</li>
<li>Microchip Technology Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) up 10.44%</li>
<li>LPL Financial Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) up 5.83%</li>
<li>Ubiquiti Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) up 14.64%</li>
<li>Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) down 2.32%</li>
<li>Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) up 20.81%</li>
<li>Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) down 7.75%</li>
<li>Alliant Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>) up 1.29%</li>
<li>Akamai Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) down 7.90%</li>
<li>EchoStar Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) up 2.77%</li>
<li>Starwood Property Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>) up 0.29%</li>
<li>Essent Group Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESNT#NYSE">ESNT</a>) down 1.45%</li>
</ul>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45317301/5-treasury-yields-could-force-trump-to-slash-tariffs-in-q2-says-bofas-hartnett">5% Treasury Yields Could Force Trump To Slash Tariffs In Q2, Says BofA&#8217;s Hartnett </a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Government

Large Cap

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Commodities

Economics

ETFs

$BTC

AKAM

COIN

SPDR Dow Jones Industrial Average ETF Trust

ESNT

EXPE

LPLA

MCHP

MNST

PODD

SATS

STWD

Select Sector SPDR-Consumer Discretionary

Stocks Slip As Gold Rebounds To $3,330, Bitcoin Holds $102,000: What's Driving Markets Friday?

Oppenheimer analyst Steven Lichtman maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Outperform and raises the price target from $312 to $324.

News

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Insulet, Raises Price Target to $324

Insulet Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) reported first-quarter adjusted earnings of $1.02 per share, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 80 cents</a>.
The automated insulin delivery technology maker reported sales of $569 million, up 28.8% year over year (29.8% in constant currency), beating the consensus of $543.4 million, exceeding the high end of the company&#8217;s guidance range of <a target="_blank" href="https://www.benzinga.com/25/02/43890152/insulets-strong-q4-highlights-surging-omnipod-demand-and-growth-potential-analyst-sees-continued-growth-in-2025" rel="noreferrer noopener">25% in constant currency</a>.
<ul class="wp-block-list">
<li>Total Omnipod revenue reached $554.1 million, an increase of 28.0%, or 29.0% in constant currency. 
<ul class="wp-block-list">
<li>U.S. Omnipod revenue of $401.7 million, an increase of 26.4%.</li>
<li>International Omnipod revenue of $152.4 million, an increase of 32.2%, or 36.1% in constant currency.</li>
</ul>
</li>
<li>Drug Delivery <a href="https://www.benzinga.com/pressreleases/25/05/b45298970/insulet-reports-first-quarter-2025-revenue-increase-of-29-year-over-year-30-constant-currency1" target="_blank" rel="noreferrer noopener">revenue of $14.9 million</a>.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" rel="noreferrer noopener">Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry</a>
Gross margin of 71.9%, up 240 basis points.
Operating income of $88.8 million, or 15.6% of revenue, up 270 basis points, compared with $56.9 million, or 12.9% of revenue, a year ago.
Adjusted operating income&nbsp;of $93.5 million, or 16.4% of revenue, up 350 basis points year over year.
Adjusted EBITDA&nbsp;of $133.9 million, or 23.5% of revenue, up 330 basis points, compared with $89.2 million, or 20.2% of revenue, a year ago.
&#8220;As <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45034103/insulet-appoints-ashley-mcevoy-president-and-ceo" rel="noreferrer noopener">Insulet&#8217;s new President and CEO</a>, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our Podders,&#8221; said Ashley McEvoy, President and CEO.
Guidance:&nbsp;For 2025, Insulet expects revenue growth between 19%-22% from a prior range of 16%-20%.
<ul class="wp-block-list">
<li>It projects Omnipod sales to increase by 20%-23% versus a previous range of 17%-21%.</li>
<li>The company expects the drug delivery sales decline to be (35)%-(25)%, compared to (55)%-(45)% anticipated earlier.</li>
</ul>
For Q2 2025, Insulet forecasts revenue growth between 23% and 26%, with U.S. Omnipod sales increasing by 22% to 25%.
William Blair analyst Margaret Kaczor Andrewon on Friday wrote, &#8220;In short, the quarter updates were positive and support our view that Insulet remains in the pole position as the pump market is on the steep part of the adoption curve by insulinintensive diabetics in the U.S. This had led to—and should continue to lead to—margin expansion. Further, recent performance and accelerating adoption of pump and Omnipod therapy internationally sets up for years of growth in a $7 billion-plus market with collective adoption rates at half or less than half of the U.S. market.&#8221;
Kaczor Andrew maintains an Outperform rating for Insulet.
Price Action: PODD stock is up 17.1% at $301.00 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45298528/comcast-gains-analyst-praise-for-parks-expansion-and-strong-wireless-despite-broadband-hurdles" target="_blank" rel="noreferrer noopener">Comcast Growth Steps Will Take &#8216;A Minimum Of Several Quarters&#8217; To Generate Returns: Analyst</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

Guidance

Health Care

Movers

Trading Ideas

General

Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad

U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Friday.
Shares of Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance <a href="https://www.benzinga.com/quote/PODD/earnings">above estimates</a>.
Insulet reported quarterly earnings of $1.02 per share which beat the analyst consensus estimate of 80 cents per share. The company reported quarterly sales of $569.00 million which beat the analyst consensus estimate of $543.40 million.
Insulet shares jumped 16.7% to $300.10 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Gogo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGO#NASDAQ">GOGO</a>) jumped 42.2% to $10.77 after the company reported better-than-expected first-quarter financial results and issued FY25 sales guidance above estimates.</li>
<li>Definitive Healthcare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) gained 42.2% to $4.00 after the company posted quarterly earnings and raised its FY25 outlook.</li>
<li>Ouster, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>) rose 26.7% to $10.96 after the company reported better-than-expected quarterly EPS results.</li>
<li>nLIGHT, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASR#NASDAQ">LASR</a>) surged 25.8% to $10.85 after the company reported better-than-expected first-quarter financial results and issued second-quarter sales guidance above estimates.</li>
<li>Natural Grocers by Vitamin Cottage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGVC#NASDAQ">NGVC</a>) gained 24.8% to $57.25. Natural Grocers partnered with Contented Hen to offer premium eggs at introductory prices.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) gained 24.7% to $74.72 after the company reported better-than-expected first-quarter financial results.</li>
<li>TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) rose 21.9% to $113.61 after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance above estimates.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 20% to $254.95.</li>
<li>Rumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) gained 18.3% to $9.21 following upbeat quarterly earnings.</li>
<li>Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) gained 16% to $42.51. Toast reported quarterly earnings of nine cents per share, which missed the Street estimate of 12 cents. Quarterly revenue came in at $1.34 billion, in line with the consensus estimate.</li>
<li>Microchip Technology Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) gained 13.7% to $55.83 after the company reported better-than-expected fourth-quarter sales results and issued first-quarter guidance above estimates.</li>
<li>Sensata Technologies Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) shares jumped 13.5% to $25.50 as the company reported better-than-expected first-quarter financial results and issued strong guidance for the second quarter.</li>
<li>AvePoint, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVPT#NASDAQ">AVPT</a>) gained 11.8% to $19.47 after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance above estimates.</li>
<li>Pinterest, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) gained 11.2% to $30.99 after the company reported better-than-expected first-quarter sales results and issued second-quarter sales guidance with its midpoint above estimates.</li>
<li>Ubiquiti Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) climbed 10.8% to $391.51 after the company reported better-than-expected third-quarter financial results.</li>
<li>Yelp Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) rose 10.7% to $39.62 following upbeat quarterly earnings.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) gained 10.1% to $18.68.</li>
<li>MINISO Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) climbed 9.4% to $20.27.</li>
<li>Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) rose 8.7% to $135.16 after the company reported better-than-expected sales results.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 7.1% to $305.13. As the electric vehicle manufacturer is finalizing plans to launch operations in the third-largest car market in the world, Prashanth Menon, the Country Head for India for Tesla, has reportedly resigned after nine years with the CEO Elon Musk-led company.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45316242/how-to-earn-500-a-month-from-nrg-energy-stock-ahead-of-q1-earnings">How To Earn $500 A Month From NRG Energy Stock Ahead Of Q1 Earnings</a></li>
</ul>

Intraday Update

Markets

AVPT

GOGO

LASR

MNSO

NGVC

OUST

PINS

PONY

TMDX

TOST

TSLA

YELP

Insulet Posts Upbeat Earnings, Joins Trade Desk, TransMedics Group, Tesla And Other Big Stocks Moving Higher On Friday

WIIM

Insulet shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance above estimates. Also, the company issued Q2 sales guidance above estimates.

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="6" rowspan="1">INSULET CORPORATION</td>
</tr>
<tr>
<td colspan="6" rowspan="1">NON-GAAP RECONCILIATIONS (UNAUDITED) CONTINUED</td>
</tr>
<tr>
<td colspan="6" rowspan="1">REVENUE GUIDANCE</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="5" rowspan="1">Year Ending December 31, 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Revenue Growth&nbsp; GAAP</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Currency&nbsp; Impact</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Constant&nbsp; Currency</td>
</tr>
<tr>
<td colspan="1" rowspan="1">U.S. Omnipod</td>
<td colspan="1" rowspan="1">18% - 21%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">—%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">18% - 21%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">International Omnipod</td>
<td colspan="1" rowspan="1">29% - 32%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">27% - 30%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Omnipod</td>
<td colspan="1" rowspan="1">21% - 24%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">1%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">20% - 23%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Drug Delivery</td>
<td colspan="1" rowspan="1">(35)% - (25)%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">—%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(35)% - (25)%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total</td>
<td colspan="1" rowspan="1">20% - 23%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">1%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">19% - 22%</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="5" rowspan="1">Three Months Ended June 30, 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Revenue Growth&nbsp; GAAP</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Currency&nbsp; Impact</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Constant&nbsp; Currency</td>
</tr>
<tr>
<td colspan="1" rowspan="1">U.S. Omnipod</td>
<td colspan="1" rowspan="1">22% - 25%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">—%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">22% - 25%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">International Omnipod</td>
<td colspan="1" rowspan="1">32% - 35%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">27% - 30%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Omnipod</td>
<td colspan="1" rowspan="1">24% - 27%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">1%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">23% - 26%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Drug Delivery</td>
<td colspan="1" rowspan="1">10% - 15%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">—%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">10% - 15%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total</td>
<td colspan="1" rowspan="1">24% - 27%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">1%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">23% - 26%</td>
</tr>
</tbody>
</table>
</figure>

Insulet Sees Q2 Sales $605.740M-$620.395M vs $577.77M Est

Insulet Raises FY2025 Sales Guidance from $2.40B-$2.49B to $2.49B-$2.55B vs $2.45B Est

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) reported quarterly earnings of $1.02 per share which beat the analyst consensus estimate of $0.80 by 27.5 percent. This is a 39.73 percent increase over earnings of $0.73 per share from the same period last year. The company reported quarterly sales of $569.00 million which beat the analyst consensus estimate of $543.40 million by 4.71 percent. This is a 28.82 percent increase over sales of $441.70 million the same period last year.

Earnings Beats

Insulet Q1 Adj. EPS $1.02 Beats $0.80 Estimate, Sales $569.00M Beat $543.40M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

U.S. stocks traded mixed at midday Wednesday, as investors remained cautious ahead of the Federal Reserve&#8217;s upcoming policy decision, with Chair Jerome Powell set to <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45258146/all-eyes-on-powell-betting-markets-reveal-what-the-fed-chair-is-most-likely-to-say-on-wednesday">speak at 2:30 p.m. ET.</a>
Trade developments continued to influence market sentiment. During a Senate hearing, Treasury Secretary Scott Bessent confirmed that initial talks with China will begin in Switzerland later this week, though he emphasized they are only preliminary.
Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) led notable decliners, plunging over 7% after a Bloomberg report indicated an Apple executive's testimony suggested AI may be eroding traditional search market share.
The Dow Jones outperformed, while tech-heavy indexes like the Nasdaq 100 and S&amp;P 500 lagged under pressure from Alphabet&#8217;s sharp decline. Sector performance was positive overall, with modest gains led by financials.
In commodities, U.S. natural gas prices at the Henry Hub surged over 5% to $3.640 per million British units, driven by recovering feedgas flows to Freeport LNG and forecasts for early-season heat boosting demand.
Gold retreated 1.5% after a strong two-day rally, while oil dipped 1.2% to $58.30 following a brief spike to $60 overnight.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) held steady at around $96,800.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,115.49</td>
<td>0.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,993.68</td>
<td>0.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,619.12</td>
<td>0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,781.12</td>
<td>-0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:10 p.m. ET </figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.2% up to $559.98.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.7% to $410.96.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.2% to $480.71.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.6% to $197.89.</li>
<li>The&nbsp;Financials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) outperformed, up 0.9%; the&nbsp;Communication Services&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) lagged, down 0.8%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
Stocks reacting to earnings included:
<ul>
<li>Arista Networks Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) down 6.84%</li>
<li>Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) up 9.16%</li>
<li>Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) up 0.89%</li>
<li>International Flavors &amp; Fragrances Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) down 6.09%</li>
<li>Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) up 0.41%</li>
<li>Mosaic Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) up 3.58%</li>
<li>Corpay Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>) down 1.80%</li>
<li>Wynn Resorts Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) up 0.56%</li>
<li>Jack Henry &amp; Associates Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>) down 0.67%</li>
<li>Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) down 0.16%</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) down 6.04%</li>
<li>Coty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) down 9.09%</li>
<li>Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) down 2.90%</li>
<li>The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) up 11.46%</li>
<li>Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) down 2.02%</li>
<li>Emerson Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) up 2.72%</li>
<li>Johnson Controls International plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) up 1.52%</li>
<li>Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) down 4.78%</li>
<li>Verisk Analytics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) up 4.22%</li>
<li>Rockwell Automation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) up 12.29%</li>
<li>Cheniere Energy Partners, L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>) down 0.82%</li>
<li>CDW Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>) up 6.90%</li>
<li>NiSource Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NI#NYSE">NI</a>) up 3.13%</li>
</ul>
Stocks slated to report earnings after the close include Fortinet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>), Axon Enterprise Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAXN#NASDAQ">AAXN</a>), Corteva Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>), Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>), Texas Pacific Land Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>), Atmos Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATO#NYSE">ATO</a>), Fidelity National Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>), and Western Gas Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WES#NYSE">WES</a>).
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45257429/michael-saylor-calls-bitcoin-the-corporate-survival-strategy-for-96-of-companies">Michael Saylor Calls Bitcoin The &#8216;Corporate Survival Strategy&#8217; For 96% of Companies</a></li>
</ul>
Powell will be speaking at 2:30 p.m. ET. Watch below.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: FOMC Rate Decision &#x7C; Fed Chair Powell Press Conference &#x7C; May 7, 2025" width="500" height="281" src="https://www.youtube.com/embed/xpIaAwIGoIA?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Photo: Shutterstock

Sector ETFs

Econ #s

Tech

AAXN

ANET

COTY

CPAY

CTVA

EPAM

EVRG

FTNT

GOOG

GOOGL

JKHY

KVUE

MTCH

NWSA

PARA

PENN

PLNT

RIVN

SHOP

SMCI

SOLV

UBER

USFD

VRSK

VTRS

WYNN

Wall Street Mixed Ahead Of Fed Meeting, Alphabet Sinks: What's Driving Markets Wednesday?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>INO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$2.00</td>
<td>$30.8K</td>
<td align="right">332</td>
<td>4.0K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/02/25</td>
<td>$820.00</td>
<td>$35.4K</td>
<td align="right">141</td>
<td>1.1K</td>
</tr>
<tr>
<td>RARE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$45.00</td>
<td>$44.3K</td>
<td align="right">255</td>
<td>1.0K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$182.50</td>
<td>$28.8K</td>
<td align="right">780</td>
<td>752</td>
</tr>
<tr>
<td>LNTH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$100.00</td>
<td>$81.1K</td>
<td align="right">468</td>
<td>324</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$165.00</td>
<td>$79.9K</td>
<td align="right">302</td>
<td>65</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$85.00</td>
<td>$34.1K</td>
<td align="right">236</td>
<td>59</td>
</tr>
<tr>
<td>PODD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$260.00</td>
<td>$35.7K</td>
<td align="right">5</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding INO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>), we observe a call option sweep with bearish sentiment. It expires in 204 day(s) on November 21, 2025. Parties traded 684 contract(s) at a $2.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $30.8K, with a price of $45.0 per contract. There were 332 open contracts at this strike prior to today, and today 4000 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on May 2, 2025. Parties traded 43 contract(s) at a $820.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $35.4K, with a price of $836.0 per contract. There were 141 open contracts at this strike prior to today, and today 1130 contract(s) were bought and sold. 
• For RARE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), we notice a call option sweep that happens to be bullish, expiring in 106 day(s) on August 15, 2025. This event was a transfer of 80 contract(s) at a $45.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $44.3K, with a price of $560.0 per contract. There were 255 open contracts at this strike prior to today, and today 1028 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option sweep that happens to be bearish, expiring in 15 day(s) on May 16, 2025. This event was a transfer of 22 contract(s) at a $182.50 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.8K, with a price of $1310.0 per contract. There were 780 open contracts at this strike prior to today, and today 752 contract(s) were bought and sold. 
• For LNTH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), we notice a put option sweep that happens to be bearish, expiring in 15 day(s) on May 16, 2025. This event was a transfer of 163 contract(s) at a $100.00 strike. This particular put needed to be split into 53 different trades to become filled. The total cost received by the writing party (or parties) was $81.1K, with a price of $500.0 per contract. There were 468 open contracts at this strike prior to today, and today 324 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option trade that happens to be bearish, expiring in 624 day(s) on January 15, 2027. This event was a transfer of 65 contract(s) at a $165.00 strike. The total cost received by the writing party (or parties) was $79.9K, with a price of $1230.0 per contract. There were 302 open contracts at this strike prior to today, and today 65 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option trade that happens to be bearish, expiring in 413 day(s) on June 18, 2026. This event was a transfer of 33 contract(s) at a $85.00 strike. The total cost received by the writing party (or parties) was $34.1K, with a price of $1035.0 per contract. There were 236 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For PODD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), we notice a put option sweep that happens to be bullish, expiring in 260 day(s) on January 16, 2026. This event was a transfer of 10 contract(s) at a $260.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $35.7K, with a price of $3570.0 per contract. There were 5 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

LNTH

RARE

8 Health Care Stocks Whale Activity In Today's Session

Insulet shares are trading lower after Wolfe Research downgraded the stock from Outperform to Peer Perform.

7 analysts have shared their evaluations of Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Insulet, presenting an average target of $324.57, a high estimate of $355.00, and a low estimate of $293.00. Marking an increase of 11.73%, the current average surpasses the previous average price target of $290.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1745931711_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Insulet by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Shagun Singh &#x7C;RBC Capital &#x7C;Announces &#x7C;Outperform &#x7C; $340.00&#x7C;- &#x7C; 
&#x7C;Joanne Wuensch &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $355.00&#x7C;$310.00 &#x7C; 
&#x7C;Jayson Bedford &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $328.00&#x7C;$294.00 &#x7C; 
&#x7C;Mathew Blackman &#x7C;Stifel &#x7C;Raises &#x7C;Hold &#x7C; $293.00&#x7C;$245.00 &#x7C; 
&#x7C;Matt O'Brien &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $310.00&#x7C;$285.00 &#x7C; 
&#x7C;Lawrence Biegelsen &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $322.00&#x7C;$305.00 &#x7C; 
&#x7C;Kyle Rose &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $324.00&#x7C;$304.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Insulet. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insulet compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Insulet's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Insulet's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PODD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Insulet analyst ratings.</a>
<h2>About Insulet</h2>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
<h3>Insulet's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Insulet displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 17.2%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Insulet's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.85% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Insulet's ROE stands out, surpassing industry averages. With an impressive ROE of 8.65%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Insulet's ROA stands out, surpassing industry averages. With an impressive ROA of 3.29%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 1.15, Insulet faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Insulet In The Eyes Of 7 Experts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan analyst Casey Woodring downgraded the rating for ICON Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Overweight to Neutral and lowered the price target from $265 to $150. Icon shares closed at $145.00 on Monday. <a href="https://www.benzinga.com/quote/ICLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Mike Polark downgraded Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) from Outperform to Peer Perform. Insulet shares closed at $259.52 on Monday. <a href="https://www.benzinga.com/quote/PODD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Daniel Imbro downgraded Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) from Overweight to Equal-Weight and lowered the price target from $515 to $255. Saia shares closed at $237.11 on Monday. <a href="https://www.benzinga.com/quote/SAIA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Pablo Monsivais downgraded the rating for Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLRS#NYSE">VLRS</a>) from Overweight to Equal-Weight and slashed the price target from $12 to $4.5. Controladora Vuela shares closed at $3.94 on Monday. <a href="https://www.benzinga.com/quote/VLRS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying SAIA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29080820/image-213-1024x589.png" alt="" class="wp-image-892692" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29080820/image-213-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29080820/image-213-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29080820/image-213-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29080820/image-213.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45060164/general-motors-coca-cola-and-3-stocks-to-watch-heading-into-tuesday">General Motors, Coca-Cola And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

ICLR

SAIA

VLRS

This Saia Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday

Wolfe Research analyst Mike Polark downgrades Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) from Outperform to Peer Perform.

Wolfe Research Downgrades Insulet to Peer Perform

2025 Outlook
Insulet expects to exceed its previously provided first quarter revenue guidance and intends to raise guidance for the full year.

Insulet Expects To Exceed Q1 Revenue Growth Outlook Of 22%-25% And Raise FY25 Revenue Growth Outlook From Prior 16%-20%

Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod&#xAE; brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately.
Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the right time to implement this leadership transition. Mr. Hollingshead has entered into a consulting arrangement with the Company to facilitate a smooth transition.
&nbsp;

Management

Insulet Names Ashley McEvoy as New CEO, Replacing Jim Hollingshead in Leadership Shakeup

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 15 years by 10.59% on an annualized basis producing an average annual return of 21.0%. Currently, Insulet has a market capitalization of $17.14 billion. 
Buying $100 In PODD: If an investor had bought $100 of PODD stock 15 years ago, it would be worth $1,693.41 today based on a price of $244.02 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745358317_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Insulet 15 Years Ago Would Be Worth This Much Today

Comments

Insulet

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL